IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein–specific PET/CT

Röhrich, Manuel; Loktev, Anastasia; Wefers, Annika K.; Altmann, Annette; Paech, Daniel; Adeberg, Sebastian; Windisch, Paul; Hielscher, Thomas; Flechsig, Paul; Floca, Ralf; Leitz, Dominik; Schuster, Julius P.; Huber, Peter E.; Debus, Jürgen; Deimling, Andreas von; Lindner, Thomas; Haberkorn, Uwe

doi:10.1007/s00259-019-04444-y

Cited by 99 publications

(76 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the GBMs and all grade III and II gliomas harbored a mutation in the Isocitrate dehydrogenase (IDH) gene. While grade II, IDH mutant gliomas showed only slight tracer uptake and low tumor-to-background ratios, grade III gliomas and GBMs showed stronger enhancement [34]. A second paper by Röhrich et al analyzed the 13 IDH-wildtype GBMs and found that FAP enhancement was not independent from but not limited to reflecting perfusion differences.…”

Section: Brainmentioning

confidence: 99%

Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review

Windisch

Zwahlen

Koerber

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

Small molecules targeting fibroblast activation protein (FAP) have emerged as a new group of tracers for positron emission tomography (PET) in 2018. The purpose of this systematic review is therefore to summarize the evidence that has been gathered to date in patients and to discuss its possible implications for radiotherapy planning. The MEDLINE database was searched for the use of FAP-specific PET in cancer patients and the records were screened according to PRISMA guidelines. Nineteen studies were included. While dedicated analyses of FAP-specific PET for radiotherapy planning were available for glioblastoma, head and neck cancers, lung cancer, and tumors of the lower gastrointestinal tract, there is still very limited data for several epidemiologically significant cancers. In conclusion, FAP-specific PET represents a promising imaging modality for radiotherapy planning that warrants further research.

show abstract

Section: Brainmentioning

confidence: 99%

Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review

Windisch

Zwahlen

Koerber

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…1). FAP-targeted PET imaging may also be attractive for detecting tumor lesions with low or heterogeneous glucose metabolism or those located in close vicinity to highly glycolytic normal tissues (16)(17)(18). Additional potential advantages include early imaging at 10 min after injection and the absence of required fasting.…”

Section: Why Is Fap-targeted Imaging Attractive?mentioning

confidence: 99%

“…68 Ga-FAPI-04 showed the most favorable properties for PET imaging (low nanomolar affinity to FAP, near-complete internalization of radioactivity bound to FAP, and rapid blood clearance) with impressive lesion-to-background ratios in patients with a broad range of cancers (26). 18 F-labeled compounds (FAPI-74, RPS-301) are being developed to improve potential commercial distribution (27)(28)(29).…”

Section: Molecular Imagingmentioning

confidence: 99%

“…To streamline research and development of FAP-targeted compounds, the nuclear medicine community (industry and academia) can learn from the National Oncologic PET Registry successes for FDG and the successful translation of 68 Ga-DOTATATE, 68 Ga-DOTATOC, 18 F-fluciclovine, and, more recently, the PSMA imaging agents. Strategies for translating FAP-targeted imaging agents may range from phase 3 diagnostic efficacy studies for each cancer type to pan-cancer diagnostic or predictive biomarker applications, respectively.…”

Section: Challengesmentioning

confidence: 99%

“…68 Ga-FAPI and18 F-FDG PET images in patients with various cancers. (Reprinted with permission of (16).…”

mentioning

confidence: 99%

See 2 more Smart Citations

FAP: The Next Billion Dollar Nuclear Theranostics Target?

Calais

2020

J Nucl Med

View full text Add to dashboard Cite

⁶⁸ Ga‐FAPI, a Twin Tracer for ¹⁸ F‐FDG in the Era of Evolving PET Imaging

Manafi‐Farid

Divband

Amini

et al. 2023

Radiology‐Nuclear Medicine Diagnostic Imaging

View full text Add to dashboard Cite

IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein–specific PET/CT

Cited by 99 publications

References 42 publications

Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review

Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review

FAP: The Next Billion Dollar Nuclear Theranostics Target?

⁶⁸ Ga‐FAPI, a Twin Tracer for ¹⁸ F‐FDG in the Era of Evolving PET Imaging

Contact Info

Product

Resources

About

IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein–specific PET/CT

Cited by 99 publications

References 42 publications

Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review

Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review

FAP: The Next Billion Dollar Nuclear Theranostics Target?

68 Ga‐FAPI, a Twin Tracer for 18 F‐FDG in the Era of Evolving PET Imaging

Contact Info

Product

Resources

About

⁶⁸ Ga‐FAPI, a Twin Tracer for ¹⁸ F‐FDG in the Era of Evolving PET Imaging